NCT07314346PHASE1RecruitingAccepts Healthy Volunteers
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone
Atea Pharmaceuticals, Inc.
Start Date
1/7/2025
Completion Date
8/1/2026
Summary
Drug-drug interaction study between Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone
Eligibility Criteria
Age Range: 18 years to 65 years
Inclusion Criteria:
* Must agree to use acceptable contraceptive methods through at least 90 days after the last dose of study drug.
* Minimum body weight of 50 kg and body mass index (BMI) of 18-32 kg/ m2.
* Willing to comply with the study requirements and to provide written informed consent.
Exclusion Criteria:
* Infected with hepatitis B virus, hepatitis C virus, HIV.
* Abuse of alcohol or drugs.
* Use of other investigational drugs within 28 days prior to Day -5.
* Concomitant use of prescription medications, or systemic over-the-counter medications (apart from methadone or buprenorphine/naloxone as assigned maintenance therapy).
* Other clinically significant medical conditions or laboratory abnormalities.
Interventions
DRUG
Buprenorphine/Naloxone + BEM/RZR
DRUG
Methadone +BEM/RZR
Conditions
Healthy Volunteer Study
Locations
Atea Study Site
Hollywood, Florida 33019
United States
Atea Study Site
Overland Park, Kansas 66212
United States
Atea Study Site
Marlton, New Jersey 08053
United States